The critical ingredient in mushrooms with psychedelic effects, psilocybin, may one day be used therapeutically via microdosing, according to recent studies.
Psilocybin is a well-known classic psychedelic drug that has lately drawn attention for its potential to help cure various psychiatric conditions, mainly addiction, and depression, through therapy combined with a high dose of psilocybin.
In this therapeutic intervention, the patient consumes psilocybin after careful medicinal preparation and has a psychedelic experience in the company of a qualified therapist. The event is then assimilated throughout numerous treatment sessions.
Repeatedly taking small doses of psilocybin, sometimes known as "microdosing," may be linked to beneficial outcomes.
What did the study tell us?
The rat study, published in the journal Molecular Psychiatry, demonstrated that the animals handled the repeated low doses of psilocybin well and did not display evidence of anxiety, decreased locomotor activity, or indicators of diminished pleasure, often known as anhedonia.
The rats were more resilient to stress after receiving repeated modest doses of psilocybin and showed fewer obsessive tendencies.
In addition, it was found that there were more connections to the thalamus, a part of the brain that acts as a sort of filter for our judgments and worries.
Since many individuals report feeling better after taking psychedelic mushrooms in tiny amounts, it may be because of the altered connection to the thalamus that we are more resilient to stressors.
The results of the current study have provided the researchers with a reliable strategy that they may use to conduct future studies on the effects of repeated low doses of psilocybin.
The study also provides evidence in favor of the many anecdotal reports highlighting the advantages of using microdosing as a therapeutic intervention. This opens the door for more investigation and even novel methods for treating mental illnesses.
There is a lot of emphasis on microdosing due to the rise in worry and tension in society, which has fueled an increase in the sale of mushrooms.
According to co-author Mikael Palner from the University of Southern Denmark, psilocybin for therapeutic use has already been approved or is being legalized in nations including the Netherlands, Australia, the United States, and Canada.
He continues, saying that since these substances are currently extensively utilized by individuals worldwide, they must comprehend their effects and adverse effects.
Now that the team has figured out the correct dose for rats, it can explore the consequences of microdosing, which might significantly increase their knowledge of the brain and mental difficulties.